• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > About > Annual reports > Annual Report 2022

2022 Africa highlights

Before, sleeping sickness was a frightening disease. But now that new treatments exist, we just see it as another disease - like malaria. I am very happy that my son can take his treatment at home. It is much simpler.

Hélène, a nurse from Masi Manimba, Democratic Republic of the Congo, sits at home with her 12-year-old son, Brinol, as he takes his sleeping sickness treatment, fexinidazole, during their lunch.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

En route to sleeping sickness elimination

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The number of reported cases of sleeping sickness has fallen sharply over the last two decades, from almost 40,000 reported cases in 1998 to less than 1,000 per year over the past five years. This remarkable progress has been driven by both the fierce commitment of frontline health staff and the availability of safer, more effective treatments. But as cases decline, awareness of the disease can wane as well – making the sustained elimination of sleeping sickness a real challenge.

In parallel with our sleeping sickness R&D programmes in the DRC and Guinea, DNDi teams and partners are also squarely focused on supporting interventions to boost and maintain access to screening and treatment. Fexinidazole, the first simple, oral treatment for both stages of T.b. gambiense sleeping sickness, delivered by DNDi and partners in 2018, is now authorized for use in all endemic countries. A majority of eligible patients received the treatment in 2022 – provided free of charge.

To safeguard progress against sleeping sickness, we continued supporting patient screening and clinical training programmes for healthcare staff in 2022 together with our partners in the HAT Platform – and published an ethnographic study to inform and tailor interventions to ensure rapid case detection and treatment and increase community awareness of the disease. Our teams and partners also began work to improve routine pharmacovigilance reporting in the Democratic Republic of the Congo, Central African Republic, Guinea, Angola, and South Sudan.

LeishAccess: Supporting policy change for better treatments

2022 was a momentous year for our teams and partners working to improve treatments for people affected by leishmaniasis in Africa. In September, DNDi and our research partners published evidence of a shorter, safer new treatment for visceral leishmaniasis (VL) combining miltefosine and paramomycin (MF+PM). In June, the World Health Organization also recommended the combination of liposomal amphotericin B and miltefosine (LAmB+MF) as an improved treatment for people living with both VL and HIV, giving hope to thousands of patients who face poor outcomes with standard VL treatment.

Together with our consortium of partners in the LeishAccess Project, DNDi continued work in 2022 to drive policy change and bolster uptake of these and other improved tools for the diagnosis and treatment of leishmaniasis in Ethiopia, Kenya, Sudan, South Sudan, and Uganda. Our teams’ efforts focused on facilitating adoption of MF+PM and LAmB+MF, as well as thermotherapy for uncomplicated cutaneous leishmaniasis and optimal treatments for post-kala-azar dermal leishmaniasis. Together with our partners, we designed country-specific work plans to support the implementation of new guidelines and best practices, disseminated the latest clinical trial results, and supported the establishment of new treatment sites at Moroto Referral Hospital in Uganda and Sigor Hospital in Kenya.

Assistant bioanalyst Neo Moqhekoana demonstrates the process of analyte extraction to NIMR and UNC Project partners at FARMOVS in Bloemfontein, South Africa. The laboratory is lit with yellow light from sodium vapour lamps to prevent light contamination of samples.

Strengthening capacity to conduct early clinical trials in Africa

Phase I clinical trials for a sustained-release formulation of flucytosine, a drug critical in the treatment of cryptococcal meningitis, were conducted at DNDi research partner FARMOVS in Bloemfontein, South Africa in 2022. In January 2023, the FARMOVS team were joined in Bloemfontein by partners from the National Institute for Medical Research (NIMR), Tanzania, and the University of North Carolina (UNC) Project Lilongwe, Malawi, to share best practices in the collection of pharmacokinetic samples ahead of a Phase II trial of the new formulation, set to begin at sites in Malawi and Tanzania in the second half of 2023. The week-long training covered patient enrolment and registration; sample collection, storage, and transport; sample analysis; and data collection.

BACK TO 2022 ANNUAL REPORT

Photo credits: Scholars-DNDi; FARMOVS/Vicky Simpson-DNDi

Stay connected

Get our latest news, personal stories, research articles, and job opportunities.

DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo